MedCity News

Takeda Drug From $4B Deal Succeeds in Two Pivotal Plaque Psoriasis Trials

CMS’ ACCESS Model: A New Push to Rewire Medicare Around Outcomes?

CMS’ new ACCESS model, slated to begin on July 1, aims to shift traditional Medicare fee-for-service toward value-based care by tying payments to patient outcomes and encouraging tech-enabled, preventive care. Experts say it could benefit digitally mature, value-focused providers first, but its overall success will hinge on clear metrics, better data sharing and sustained participation.

By Katie Adams

MedCity Influencers

Breakthrough Therapies Aren’t Enough: What Neurology Needs Now

With new therapies being approved, and many others in the pipeline, they raise a critical question: Is our healthcare system prepared to deliver them effectively and sustainably?

By Adeyoola "Yoola" Adeniji

MedCity Influencers

Changes Are Coming to 2026 Medicare Benefits

Here are three things providers should consider when it comes to Medicare.

By Jeffrey T. King

Latest Video

Latest News

Consumer / Employer, Health Tech

Ovarian and Cervical Cancer Awareness. Woman Holding Teal Ribbon on Lower Abdomen, Uterus, Female Reproductive System, Women's Health, PCOS and Gynecology

Teal Health Teams Up With Thatch to Expand Access to Cervical Cancer Screening

Through a new partnership, Thatch’s employer customers can now offer Teal Health’s at-home cervical cancer screening as an employee benefit through an ICHRA.

By Marissa Plescia

The Power of One: Redefining Healthcare with an AI-Driven Unified Platform

In a landscape where complexity has long been the norm, the power of one lies not just in unification, but in intelligence and automation.

By David Cohen, Chief Product & Technology Officer, Greenway Health

BioPharma, Pharma

GSK Gets FDA Approval for New Severe Asthma Drug With a Dosing Advantage

GSK’s Exdensur requires just two injections a year to treat severe asthma. Less frequent injections give this new biologic medicine a dosing edge over one of GSK’s own blockbuster respiratory products as well as severe asthma drugs from companies such as AstraZeneca, Sanofi, and Amgen.

By Frank Vinluan

MedCity Influencers

When Inaction Becomes Negligence in the Age of AI

We are on the cusp of being held accountable not just for what we did wrong, but for what we failed to do, especially when readily available, life-saving technology could have made a difference.

By Dr. David Atashroo

MedCity Influencers

Beyond the Numbers: Every Data Point Tells a Different Story

While data and cost are important elements in recognizing issues, the measure of success isn’t just about the data or the numbers; it’s about ensuring that older adults can manage and maintain their expectations about health and aging in place.

By Krithika Srivats

Health Tech

Auxira Health Secures $7.8M for Virtual Cardiology Platform

Auxira Health's $7.8 million round was led by Route 66 Ventures and Abundant Venture Partners and included participation from DigiTx Partners, American Heart Association Ventures, Ensemble Innovation Ventures and City Light Capital.

By Marissa Plescia

The old lady enjoys life, travels by car and is happy to recover from her illness. A new life

Hundred Health Emerges from Stealth to Turn Health Data into Daily Action

Hundred Health emerged from stealth with an app that pulls together users’ medical records, lab results, wearable data and lifestyle information to create personalized, evidence-based 100-day health plans.

By Katie Adams

Artificial Intelligence, BioPharma

How Precision Medicine and AI are Evolving: An MD Anderson Perspective

Dr. Prajnan Das, department chair of Gastrointestinal (GI) Radiation Oncology at MD Anderson Cancer Center, talks about how precision medicine has evolved and how AI may actually be the technology that supercharges the conversion of the knowledge about human biology to personalized treatments that work.

By Arundhati Parmar

BioPharma, Pharma

AstraZeneca, Daiichi Sankyo ADC Enhertu Moves Up to First-Line Use in Breast Cancer

FDA approval for Enhertu as a first-line breast cancer treatment is important because many patients with HER2-positive cancer do not live long enough to receive a second line of therapy. In Enhertu’s pivotal study in this setting, the HER2-targeting ADC helped patients live more than three years without disease progression or death.

By Frank Vinluan

MedCity Influencers

Is Your Medical Group Ready for the January Cash Flow Crisis?

It doesn’t have to be this way. For the medical groups that lay the right foundation for patient collections, January is simply business as usual. Here are four ways to get ahead of the inevitable deductible reset.

By Tom Furr

MedCity Influencers

A Moment of Opportunity to Expand Healthcare Access in the US

These two promising changes in national healthcare policy could transform access to care for millions of Americans.

By Dr. Cole Barfield

Policy

Coalition of Pharmacy Groups Urges Congress to Enact PBM Reform

A coalition of major pharmacy organizations urged Congressional leaders to enact long-stalled PBM reforms to curb anti-competitive practices, lower drug costs and stop accelerating pharmacy closures that are limiting patient access to care.

By Marissa Plescia